- 中文名稱
RAN 一抗
- 英文名字
- RAN Primary antibody
- 供應(yīng)商
- Promab
- 產(chǎn)品貨號(hào)
- PMB-30993
- 產(chǎn)品報(bào)價(jià)
- ¥詢價(jià)/100ul

- 產(chǎn)品說明書
- 點(diǎn)擊查看
- 購買方式
- Promab中國區(qū)現(xiàn)貨中心已經(jīng)建立,95%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金,在線支付寶及網(wǎng)銀支付,或直接與我們電話聯(lián)系。本公司所有產(chǎn)品僅供科研使用,不用于臨床診斷。
- 產(chǎn)品新聞

- 背景資料
- RAN (ras-related nuclear protein) is a small GTP binding protein belonging to the RAS superfamily that is essential for the translocation of RNA and proteins through the nuclear pore complex. The RAN protein is also involved in control of DNA synthesis and cell cycle progression. Nuclear localization of RAN requires the presence of regulator of chromosome condensation 1 (RCC1). Mutations in RAN disrupt DNA synthesis. Because of its many functions, it is likely that RAN interacts with several other proteins. RAN regulates formation and organization of the microtubule network independently of its role in the nucleus-cytosol exchange of macromolecules. RAN could be a key signaling molecule regulating microtubule polymerization during mitosis. RCC1 generates a high local concentration of RAN-GTP around chromatin which, in turn, induces the local nucleation of microtubules. RAN is an androgen receptor (AR) coactivator that binds differentially with different lengths of polyglutamine within the androgen receptor. Polyglutamine repeat expansion in the AR is linked to Kennedy's disease (X-linked spinal and bulbar muscular atrophy). RAN coactivation of the AR diminishes with polyglutamine expansion within the AR, and this weak coactivation may lead to partial androgen insensitivity during the development of Kennedy's disease.
- 應(yīng)用類型
- WB,IHC,ICC,FCM
- 免疫原
- Purified recombinant fragment of human RAN (AA: 1-216) expressed in E. Coli.
- 來源宿主
- Mouse
- 反應(yīng)性
- Human,Mouse,Monkey,Rat
- 保存建議
- 4℃短期保存;-20℃長(zhǎng)期保存。避免凍融循環(huán)。
- 其他
- ProMab 生物技術(shù)公司通過整合生物信息學(xué)、分子生物學(xué)、蛋白質(zhì)表達(dá)、純化技術(shù)、基因克隆、微生物學(xué)和免疫學(xué),利用新型高通量技術(shù)開發(fā)重組蛋白、抗體和工程細(xì)胞系并將其商業(yè)化。專注于免疫治療領(lǐng)域,特別是 CAR-T/NK 細(xì)胞技術(shù)。ProMab 還開發(fā)了一種新型的 mRNA 脂質(zhì)納米顆粒(mRNA-LNP)平臺(tái),用于即用型試劑和定制研究服務(wù),以推進(jìn)現(xiàn)有產(chǎn)品并擴(kuò)展到更多的研究領(lǐng)域。

- 注意
-
該頁面的中文產(chǎn)品信息的翻譯,僅供參考。準(zhǔn)確的產(chǎn)品信息請(qǐng)以廠家的英文說明書為準(zhǔn)。下單前,請(qǐng)瀏覽說明書確認(rèn)。
-